Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
Tick-borne encephalitis vaccine · 8 trials · 2 indications
Percentage of participants achieving NT titer greater than or equal to (\>=) 10.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule. |
| 2 | EXPERIMENTAL | Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule. |
| Name | Type | Description |
|---|---|---|
| Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) | BIOLOGICAL | Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360 |
| Tick-borne Encephalitis Vaccine | BIOLOGICAL | - |
Inclusion Criteria: Male and female children will be eligible for participation in this study if: * they are aged \>= 1 years (from the 1st birthday) to 11 years (to the last day before the 12th birthday) at screening; * their parents / legal guardians provide written informed consent; * children ...
The tick-borne encephalitis vaccine is used to prevent tick-borne encephalitis, a viral infection of the central nervous system transmitted by tick bites. It is an inactivated vaccine developed by Pfizer, Inc. (NYSE: PFE) and is given to healthy children and adults to protect against the disease.
The tick-borne encephalitis vaccine is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company responsible for the vaccine's clinical development program, including the Phase 3 trials that have evaluated its immunogenicity and safety in children and adults.
The tick-borne encephalitis vaccine is in Phase 3 clinical development. It has completed eight clinical trials, including Phase 3 studies, and is not yet approved. The vaccine remains an investigational product undergoing evaluation for the prevention of tick-borne encephalitis.
The tick-borne encephalitis vaccine has been studied in eight completed clinical trials, including NCT00840801, a Phase 3 immunogenicity and safety study in children; NCT00161876, a Phase 3 follow-up study in adults aged 16 to 66; and NCT00161889 and NCT00161850, Phase 2 follow-up studies in children.
Yes, the tick-borne encephalitis vaccine is also known as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated). The two names refer to the same inactivated vaccine developed by Pfizer, Inc. (PFE) for the prevention of tick-borne encephalitis.
Across eight completed clinical trials, 9,305 participants have been enrolled in studies of the tick-borne encephalitis vaccine. The trials were randomized, double-blind, and controlled, and included healthy volunteers ranging from children as young as 1 year to adults up to 66 years of age.